here is how I look at things - we're still sitting at $1.17 - I do believe the company is in much better shape more now then ever - I like lewis in the driver seat - but here is my ?'s. why are we not signing any partners for arikace - wasn't a japan partner suppose to enter the mix? if we needed to raise $$ so bad and they say they are not going to pursue iplex then sell iplex to raise the $$ for arikace. would I sell iplex - no way as I know it's worth billions to some big pharma.
with so many ?'s an investor could ask I hope we can more clarity on the next conference call - btw does anybody know when that is expected?
and one has to wonder why fud is on such a rampage as of late compared to the sooooo knowledgeable fud we once knew
"and one has to wonder why fud is on such a rampage as of late compared to the sooooo knowledgeable fud we once knew "
As you seem to be one of the few using this board lacking the intelligence to understand my posts - I'm concerned by role of the Company directors in the destruction of the massive actual and potential shareholder value we suffered as a result of an offering at below $10 as share instead of above $20 a share.
I'm also concerned about the prospect of the share price now stagnating at the current level because the remaining demand for shares is likely to be substantially outweighed by selling pressure.
Feel free to ask questions until you fully understand my concerns.
wow! a good point. Positioning strength but I don't think that is where the company will spend the new 68M.
Insmed has said they would like to partner in Japan but that is with an approval which is 18++ months away.